Article Text

Download PDFPDF
Tendency towards erosive regression on magnetic resonance imaging at 12 months in rheumatoid arthritis patients treated with rituximab

Statistics from Altmetric.com

Footnotes

  • Competing interests: Declared. MØ has received consulting fees, speaking fees and/or research grants from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genmab, Glaxo-SmithKline, Leo Pharma, Novartis, Novo, Pfizer, Roche, Schering-Plough, UCB-Nordic and Wyeth. MSH has received consulting fees, speaking fees and/or research grants from Bristol-Myers Squibb, Roche, Schering-Plough and Wyeth.

  • Funding: Roche Denmark gave financial support but had no influence on the planning, analysis or manuscript preparation.

  • Ethics approval: The study had local ethics committee approval and followed the Declaration of Helsinki.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.